Valbiotis is participating in the prestigious Keystone Symposium in Banff, Canada, dedicated to the pathophysiology of metabolic liver diseases from March 19 to 23, 2023. The Keystone symposia, must-see event for innovation in the life sciences, bring together scientists from around the world on topics combining advances in basic research and clinical development by industrial players.
Valbiotis presents promising preclinical results obtained with its active substance TOTUM•448 against these metabolic liver disorders (NAFL and NASH), including efficacy results on steatosis and certain pathophysiological mechanisms.
View the poster 